IDO1 and glioblastoma: Evidence shows that one of the limiting enzymes of the KP, the indoleamine-2,3-dioxygenase (IDO), is overexpressed in different neoplasms including GBM, and its expression levels correlate with increased tumor-infiltrated TAM and Treg and with patient poor prognosis [115–118].